International Biological Standards for Coagulation Factors and Inhibitors

ABSTRACT

The use of international biological standards during the last 30 years has proved extremely successful in promoting global harmonization of estimates between laboratories and methods. Experience has led to the identification of physical criteria essential for standards to be suitable for long-term use. High precision of liquid filling coupled with low residual moisture and oxygen and the use of sealed glass ampoules have been found consistent with homogeneous and stable International Standards (ISs). Most plasma coagulation factors and inhibitors are calibrated in International Units (IU), which are defined as the amount of analyte in 1 mL of normal pooled plasma. Adoption of the IU has provided clarity in the definition of normal and abnormal states and has facilitated dose calculation for replacement therapy. The assay of like-versus-like materials (e.g., concentrate versus concentrate) has been found to improve interlaboratory agreement and there are now both plasma and concentrate ISs available for many coagulation factors and inhibitors. Studies into the assay of recombinant factor VIII have indicated that additional measures, such as modifications to assay methodology, are necessary to reduce interlaboratory variability. This experience may prove valuable in the future, when we have to deal increasingly with the challenges to standardization associated with the products of bioengineering.

International Standard - coagulation factors - factor VIII - hemophilia

REFERENCES

• 1 Burn J H, Finney D J, Goodwin L G. Biological Standardization. 2nd ed. Oxford, United Kingdom; Oxford University Press 1950
• 2 Jeffcoate S L. From insulin to amylin: 75 years of biological standardization in endocrinology.  Dev Biol Stand. 1999;  100 39-47
• 3 Bangham D R, Biggs R, Brozovic M, Denson K WE, Skegg J L. A biological standard for measurement of blood coagulation factor VIII activity.  Bull World Health Organ. 1971;  45 337-351
• 4 Barrowcliffe T W, Tydeman M A, Kirkwood T BL, Thomas D P. Standardization of factor VIII. III: establishment of a stable reference plasma for factor VIII-related activities.  Thromb Haemost. 1983;  50 690-696
• 5 Hubbard A R, Rigsby P, Barrowcliffe T W. Standardization of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard.  Thromb Haemost. 2001;  85 634-638
• 6 Hubbard A R. Standardization of Protein S in plasma: calibration of the 1st International Standard.  Thromb Haemost. 1997;  78 1237-1241
• 7 Gaffney P J, Wong M Y. Collaborative study of a proposed international standard for plasma fibrinogen measurement.  Thromb Haemost. 1992;  68 428-432
• 8 Whitton C M, Sands D, Hubbard A R, Gaffney P J. A collaborative study to establish the 2nd International Standard for fibrinogen plasma.  Thromb Haemost. 2000;  84 258-262
• 9 Seegers W H, Brinkhous K M, Smith H P, Warner E D. The purification of thrombin.  J Biol Chem. 1938;  126 91-95
• 10 Whitton C, Sands D, Lee T, Chang A, Longstaff C. A reunification of the US (“NIH”) and International Unit into a single standard for thrombin.  Thromb Haemost. 2005;  93 261-266
• 11 Recommendations for the preparation, characterisation and establishment of international and other biological reference standards (revised 2004). WHO Technical Report Series 2007. Geneva, Switzerland; WHO 2007 932: 73-131
• 12 Campbell P J. International biological standards and reference preparations. 1. Preparation and presentation of materials to serve as standards and reference preparations.  J Biol Stand. 1974;  2 249-258
• 13 Hubbard A R, Sands D, Chang A C, Mazurier C. Standardization of von Willebrand factor in therapeutic concentrates: calibration of the 1st International Standard for von Willebrand Factor Concentrate (00/514).  Thromb Haemost. 2002;  88 380-386
• 14 Hubbard A R. von Willebrand factor standards for plasma and concentrate testing.  Semin Thromb Hemost. 2006;  32 522-528
• 15 Raut S, Bevan S, Hubbard A R, Sands D, Barrowcliffe T W. A collaborative study to establish the 7th International Standard for Factor VIII Concentrate.  J Thromb Haemost. 2005;  3 119-126
• 16 Hubbard A R, Heath A B. Standardization of factor VIII and von Willebrand factor in plasma: calibration of the WHO 5th International Standard (02/150).  J Thromb Haemost. 2004;  2 1380-1384
• 17 Kirkwood T BL. Predicting the stability of biological standards and products.  Biometrics. 1977;  33 736-742
• 18 Kirkwood T BL, Tydeman M S. Design and analysis of accelerated degradation tests for the stability of biological standards II. A flexible computer program for data analysis.  J Biol Stand. 1984;  12 207-214
• 19 Kirkwood T BL, Barrowcliffe T W. Discrepancy between 1-stage and 2-stage assay of factor VIII:C.  Br J Haematol. 1978;  40 333-338
• 20 Barrowcliffe T W, Kirkwood T BL. Standardization of factor VIII. I. Calibration of British standards for factor VIII clotting activity.  Br J Haematol. 1980;  46 471-481
• 21 Barrowcliffe T W, Tydeman M S, Kirkwood T BL, Thomas D P. Standardization of factor VIII.III. Establishment of a stable reference plasma for factor VIII-related activities.  Thromb Haemost. 1983;  50 690-696
• 22 Barrowcliffe T W. Standardization and assay.  Semin Thromb Hemost. 1993;  19 73-79
• 23 Hubbard A R, Parr L J. Potency estimation of activated factor VII concentrates.  Thromb Haemost. 1991;  65 1160
• 24 Barrowcliffe T W, Thomas D P. The provision of standards for blood coagulation factors. In: Poller L Recent Advances in Blood Coagulation. Volume 4. Edinburgh, United Kingdom; Churchill Livingstone 1985: 251-266
• 25 Kirschbaum N, Wood L, Lachenbruch P et al.. Calibration of the Ph. Eur. BRP batch 3/MEGA 2 (US/FDA) Standard for human coagulation factor VIII concentrate for use in the potency assay.  Pharmeuropa Spec Issue Biol. 2002;  1 31-64
• 26 Barrowcliffe T W, Raut S, Sands D, Hubbard A R. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.  Semin Thromb Hemost. 2002;  28 247-255
• 27 Barrowcliffe T W. for the Factor VIII and Factor IX sub-committee . Recommendations for the assay of high-purity factor VIII concentrates.  Thromb Haemost. 1993;  70 876-877
• 28 Assay of human coagulation factor VIII (2.7.4). In: European Pharmacopoeia. 5th ed. Strasbourg, France; Council of Europe 2005: 194-195
• 29 Lamb M A, Fricke W A, Rastogi S C. Standardization of factor IX: standards for purified factor IX concentrates.  Thromb Haemost. 1991;  66 548-551
• 30 Hubbard A R, Weller L J, Bevan S A. A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates.  Br J Haematol. 2002;  117 247-248
• 31 Lee C, Barrowcliffe T W, Bray G et al.. Pharmacokinetic in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil-M.  Thromb Haemost. 1996;  76 950-956
• 32 Hubbard A R, Sands D, Sandberg E, Seitz R, Barrowcliffe T W. A multi-centre collaborative study on the potency estimation of ReFacto.  Thromb Haemost. 2003;  90 1088-1093
• 33 Hubbard A R, Weller L J, Bevan S A. Activation profiles of FVIII in concentrates reflect one-stage/chromogenic potency discrepancies.  Br J Haematol. 2002;  117 957-960
• 34 Khrenov A V, Ananyeva N M, Saenko E L. Role of the B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X.  Blood Coagul Fibrinolysis. 2006;  17 379-388
• 35 Assay of human coagulation factor VIII (2.7.4). In: European Pharmacopoeia. 5th ed. Strasbourg, France; Council of Europe Suppl 5.5. 2006: 4119-4120
• 36 Pipe S W, Saint-Remy J-M, Walsh C E. New high-technology products for the treatment of haemophilia.  Haemophilia. 2004;  10(suppl 4) 55-63